Arvinas, Inc.
As of Oct 22, 2026, Arvinas is in Stage 4, the downtrend phase, now in week 3 (since Oct 5, 2026). It closed at $7.72, 44.2% below its 52-week high and below its 200-day average, which is falling.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ARVN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ARVN among Biotechnology249th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …249 | ARVN | Stage 4 · wk 3 | 39 | −1.4% |
Arvinas: quick answers
What stage is Arvinas in?
As of Oct 22, 2026, Arvinas (ARVN) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 5, 2026 and is in week 3. What the four stages mean
Is Arvinas in an uptrend?
No. Arvinas is in a Stage 4 downtrend. It trades 21.4% below its 200-day average, which is falling.
How far is Arvinas from its 52-week high?
Arvinas closed at $7.72 on Oct 22, 2026, 44.2% below its 52-week high of $13.83. Its 52-week low is $6.82.
How has Arvinas performed over the past year?
As of Oct 22, 2026, Arvinas is down 20.1% over the past year and down 32.7% so far in 2026.
Which sector and industry is Arvinas in?
Arvinas is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma G12D protein for the treatment of cancers with the G12D mutation comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), which are investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.